AlloSource has announced that the first patients have been enrolled in a randomised controlled study to evaluate the effectiveness of AlloWrap amniotic membrane for the reduction of postoperative soft tissue inflammation in two-level anterior cervical discectomy and fusion (ACDF) procedures.
“Though I have performed many successful anterior cervical discectomy and fusion procedures, I am always looking for ways to improve patient outcomes,” said Paul Kim, The Spine Institute of San Diego, San Diego, USA. “I am looking forward to the impact AlloWrap has on helping me with my ultimate goal of relieving patient pain and returning them to a normal life.”
According to AlloSource, the AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair in a multitude of procedures. The company states that regardless of the surgical approach, the product is ideal for spinal procedures because when used as a surgical barrier the dual-sided design provides covering and protection from the surrounding environment to support the body’s natural ability to ease potential complications such as inflammation, scarring and adhesion.
The company reports that the AlloWrap DS has a moist, hydrated format that is especially suitable for endoscopic and minimally invasive surgical applications, whereas AlloWrap Dry is dehydrated for precision open-surgical placement.
“Previous animal studies using AlloWrap showed anti-inflammatory response,” said Ross Wilkins, AlloSource senior medical director. “AlloWrap has been used in other areas of the body for years, and this clinical study will deepen our understanding of its impact in spine applications too.”